PT-141 Research for Sexual Dysfunction
An evidence-based overview of research examining PT-141 in the context of sexual dysfunction. This page synthesizes findings from peer-reviewed literature.
Research Summary
PT-141 was FDA-approved in 2019 (as Vyleesi) for hypoactive sexual desire disorder (HSDD) in premenopausal women. It is the first FDA-approved treatment acting through melanocortin receptors for sexual dysfunction. The drug increases sexual desire through central nervous system mechanisms, not peripheral vasodilation. Clinical trials showed significant improvements in sexual desire and distress measures. Administration is via subcutaneous injection 45 minutes before anticipated sexual activity. Common side effects include nausea, flushing, and headache.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Sexual Dysfunction
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. PT-141 may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.